Predictive Technology Group, Inc. announced that on May 7, 2021, the company entered into a strategic development agreement (the "Agreement") with Nebula Genomics ("Nebula"). Under the terms of the Agreement, the company may offer Nebula products to its customers, including 30x whole genome sequencing testing, analytical tools, and other products and services, which are fulfilled by Nebula. The Agreement includes a revenue sharing arrangement between the company and Nebula. Nebula has agreed to provide the company with technologies and services to assist in Direct-To-Consumer ("DTC") and clinical diagnostic markets including privacy technologies, such as blockchain, and analytical tools. The company and Nebula intend to pursue joint development of proprietary diagnostics by leveraging assets, expertise, and development platforms. These development activities are expected to be governed by joint scientific and medical advisory boards with representation from both companies.